Albany Molecular Research Inc. Stock Upgraded (AMRI)

Editor's Note: Any reference to TheStreet Ratings and its underlying recommendation does not reflect the opinion of TheStreet, Inc. or any of its contributors including Jim Cramer or Stephanie Link.

NEW YORK ( TheStreet) -- Albany Molecular Research (Nasdaq: AMRI) has been upgraded by TheStreet Ratings from hold to buy. The company's strengths can be seen in multiple areas, such as its solid stock price performance, impressive record of earnings per share growth, compelling growth in net income, largely solid financial position with reasonable debt levels by most measures and reasonable valuation levels. We feel these strengths outweigh the fact that the company shows low profit margins.

  • EXCLUSIVE OFFER: Jim Cramer's Protégé, Dave Peltier, only buys Stocks Under $10 that he thinks could potentially double. See what he's trading today with a 14-day FREE pass.

Highlights from the ratings report include:
  • Powered by its strong earnings growth of 100.00% and other important driving factors, this stock has surged by 94.75% over the past year, outperforming the rise in the S&P 500 Index during the same period. Regarding the stock's future course, although almost any stock can fall in a broad market decline, AMRI should continue to move higher despite the fact that it has already enjoyed a very nice gain in the past year.
  • ALBANY MOLECULAR RESH INC reported significant earnings per share improvement in the most recent quarter compared to the same quarter a year ago. The company has demonstrated a pattern of positive earnings per share growth over the past two years. We feel that this trend should continue. During the past fiscal year, ALBANY MOLECULAR RESH INC turned its bottom line around by earning $0.40 versus -$0.12 in the prior year. This year, the market expects an improvement in earnings ($0.77 versus $0.40).
  • The net income growth from the same quarter one year ago has significantly exceeded that of the S&P 500 and the Life Sciences Tools & Services industry. The net income increased by 134.4% when compared to the same quarter one year prior, rising from $1.92 million to $4.49 million.
  • The current debt-to-equity ratio, 0.50, is low and is below the industry average, implying that there has been successful management of debt levels. Along with this, the company maintains a quick ratio of 5.38, which clearly demonstrates the ability to cover short-term cash needs.

Albany Molecular Research, Inc., a contract research and manufacturing organization, offers drug discovery, development, and manufacturing services to pharmaceutical and biotechnology companies in the United States, Europe, and Asia. Albany Molecular Research has a market cap of $492.6 million and is part of the health care sector and drugs industry. Shares are up 54.6% year to date as of the close of trading on Wednesday.

You can view the full Albany Molecular Research Ratings Report or get investment ideas from our investment research center.

3x UPSIDE POTENTIAL: TheStreet Quant Ratings has identified a handful of stocks that can potentially TRIPLE in the next 12-months. Learn more.
Disclosure: TheStreet's editorial policy prohibits staff editors, reporters and analysts from holding positions in any individual stocks.

If you liked this article you might like

EY's Greene Sees More Med Tech, CRO Deals Ahead

EY's Greene Sees More Med Tech, CRO Deals Ahead

Biotech Movers: Albany Molecular Shares Soar on Sale to PE Firms

Biotech Movers: Albany Molecular Shares Soar on Sale to PE Firms

Albany Molecular Research (AMRI) Is Weak On High Volume Today

Albany Molecular Research (AMRI) Is Weak On High Volume Today

Insider Trading Alert - MGRC, GUID And AMRI Traded By Insiders

Insider Trading Alert - MGRC, GUID And AMRI Traded By Insiders

Insider Trading Alert - NTGR, SCOR And AMRI Traded By Insiders

Insider Trading Alert - NTGR, SCOR And AMRI Traded By Insiders